PCI – 7th June 2024
Thermofisher: Thu 29 February 2024, 11:15

Current Edition

Cell and Gene Therapy

Upcoming Events

SLAS Europe – 7th April 2025
Biotechnology Show 2025: 20th January 2025

Advertisement

Fujifilm rectangle: Fri 22 November 2024, 14:23
Roald Dahl Charity: Fri 15 November 2024, 12:57
A&M STABTEST: Fri 21 June 2024, 11:43
CDD Vault – 18.03.2025
Biopharma Group – 19th March 2025
news

Adcendo Raises $135m for Cancer ADCs, and Other Financings

Adcendo has tapped into the strong investor appetite for companies developing antibody-drug conjugates for cancer with an oversubscribed second round that raised $13...
Continue Reading →
Volume 5 Issue 3

ADCs – From Lab to Clinical Development

Antibody-drug conjugates (ADCs) are a family of targeted therapeutic agents for the treatment of cancer. Compared to traditional small-molecule approaches, ADCs offer...
Continue Reading →
news

Early tests suggest Vir, GSK antibody could hold up versus omicron

Omicron's detection last week triggered travel restrictions and renewed public health measures around the world as scientists and government officials warned the vari...
Continue Reading →
news

Regeneron warns its antibody drug may be less potent versus omicron

Regeneron's drug is the top-selling COVID-19 treatment in the U.S., one of three antibody drugs currently authorized by the Food and Drug Administration for people wh...
Continue Reading →
news

Sphere Fluidics closes a $40 million funding round led by Sofinnova Partners and Redmile Group

Cambridge, UK, 28 October 2021: Sphere Fluidics, a company that has developed and is commercialising single cell analysis systems underpinned by its proprietary picod...
Continue Reading →
news

US stocks up on COVID-19 antibody drugs amid shortage concerns

The antibody treatments from Regeneron and Eli Lilly have been proven effective in reducing the risk of hospitalization or death from COVID-19 in certain high-risk in...
Continue Reading →
news

AACR 2018: GamaMabs Pharma to present new data on expression of Anti-Müllerian Hormone type II Receptor in non-gynecological cancers and on first ADC candidate targeting AMHRII

AMHRII expression and Antibody-Drug Conjugate preclinical data suggest potential broader applications for anti-AMHRII-based therapy GamaMabs Pharma, a biotechnolog...
Continue Reading →
Newcells 3 June 2024, 15:12
Aldevron: 16th January 2025
Richter: Wed 23 October 2024, 09:03
Tosoh – 29.04.25
Eppendorf – 18.03.2025
Asychem – 10.04.2025
Taconic Biosciences – 29.04.25
Steribar – 12.05.2025